Flash glucose monitoring system in patients with type 1 diabetes in healthcare center in Brazil: real world data from a short-term prospective study

Arch Endocrinol Metab. 2023 Mar 30;67(3):289-297. doi: 10.20945/2359-3997000000540. Epub 2022 Dec 1.

Abstract

Objective: To evaluate the alternate use of flash glucose monitoring (FGM) with self-monitoring blood glucose (SMBG), in patients with type 1 diabetes (T1D).

Materials and methods: Two weeks of open FGM (P2), both preceded (P1) and followed by 2 weeks (P3) of SMBG with a blinded FGM system. Mean absolute relative difference (MARD) was calculated by (|FGMi - SMBGi|) / SMBGi, where it was a paired data sample.

Results: In total, 34 patients were evaluated. Time in range (TIR) did not change between P1 and P2. In 12 patients (35.3%), TIR increased from 40% at P1 to 52% at P2 (p = 0.002) and in 22 (64.7%), TIR decreased or did not change. FGM use resulted in decreased % time spent in hypoglycemia (<70 mg/dL) (6.5% vs. 5.0%; p = 0.005), increased % time spent in hyperglycemia (>180 mg/dL) (44.5% to 51%; p = 0.046) with no significant change in % TIR. The proportion of patients who reached sensor-estimated glycated hemoglobin (eA1c) < 7% decreased from 23.5% at P1 to 12.9% at P2, p = 0.028. For the whole sample, the MARD between the two methods was 15.5% (95% CI 14.5-16.6%). For normal glucose range, hyperglycemic levels and hypoglycemic levels MARD were 16.0% (95% CI 15.0-17.0%), 13.3% (95% CI 11.5-15.2%) and 23.4% [95% CI 20.5-26.3%)], respectively.

Conclusion: FGM after usual SMBG decreased the % time spent in hypoglycemia concomitant with an undesired increase in % time spent in hyperglycemia. Lower accuracy of FGM regarding hypoglycemia levels could result in overcorrection of hypoglycemia.

Keywords: Flash glucose monitoring system; FreeStyle Libre; continuous glucose monitoring; glycated hemoglobin; glycemic control; hypoglycemia; time in range.

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring / methods
  • Brazil
  • Delivery of Health Care
  • Diabetes Mellitus, Type 1*
  • Glucose
  • Humans
  • Hyperglycemia*
  • Hypoglycemia*
  • Hypoglycemic Agents / therapeutic use
  • Prospective Studies

Substances

  • Blood Glucose
  • Glucose
  • Hypoglycemic Agents